Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yondelis + Doxil in advanced ovarian cancer
NCT01846611Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Primary completion
- Jan 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of trabectedin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Survival up to 4.3 years. Started Oct 2013; status: completed.
02
Drugs
trabectedin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01846611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01846611.